skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Going to do a little re-balancing and the result will be the addition of one new { possibly two depending on your answer } stocks to the portfolio ...... Between ISRG, CPH, GLXY, and MDA please rank from first choice to last giving each a numerical score between one and ten with ten being best . This will allow me to evaluate how much you like one better than the other ......Also a short blurb on each explaining why ......Thanks for your terrific service Garth ......
Read Answer Asked by Garth on October 30, 2024
Q: Just finished reading both questions and your report on CPH ..... I don't see any resemblance between your report and the current company .... Could you give me the " Cole's Notes " review of the state of the current company ? What's positive in the pipeline ? What's negative ? I see the failure of the nail fungus drug initially dropped the stock $5 but it has recovered since. Does that mean the drug is not dead ? Thanks for your terrific service ..... { any plans to update that report ? }
Read Answer Asked by Garth on October 17, 2024
Q: Hi 5i Team,

Would you still endorse a purchase of TMDX, CLBT, ASPN and CPH? When looking at the recent momentum of FLUT and DUOL would you still be buyers of these companies? What would be your order of preference if you were buying today?

Thanks as always,
Jon
Read Answer Asked by Jonathan on September 25, 2024
Q: Share this news no queston

MISSISSAUGA, ON, Sept. 13, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that it has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015, a product for the treatment of nail fungus. Moberg has noted that the number of patients who have achieved clinical cure in this blinded subset of patients is lower than its expectations, which necessitates that Moberg inform the market about this fact.

Moberg's full press release can be found here.

Cipher owns the Canadian marketing rights to Moberg's MOB-015 through a licensing agreement (the "Agreement") dated September 18, 2018, to commercialize, promote, sell and distribute the product exclusively in Canada. On signing the Agreement, the Company paid an upfront amount of US$0.5 million and any future additional payments of up to US$14.1 million are contingent upon successful achievement of certain clinical data results as well as development, regulatory and commercial sales milestones. Cipher has no further financial obligations in respect of the Agreement if the applicable development and regulatory milestones outlined in the Agreement are not attained.

The Company will continue to collaborate with its partner Moberg as full results from their clinical trial become available, however this pipeline product does not impact the sales and earnings profile of Cipher's existing business today.

The Company continues to be focused on its recent acquisition of the NatrobaTM business from ParaPRO LLC as announced on July 29, 2024, as well as other potential growth opportunities. The Company believes the growth potential for the NatrobaTM product in the U.S. market and other markets internationally is significant, and the integration of this business into its existing profitable North American platform remains Cipher's focus and priority in the near term.
Read Answer Asked by fwb181 on September 13, 2024
Q: Cipher Pharma made a major acquisition today that they say will double their sales and profits. The new products acquired are also superior to the existing treatment, which has 71% of the USA market, so lots of room there for growth, plus they plan to get approval in Canada and make a deal for ex-North America sales. They also have their drug for toenail fungus, a big market, set to produce final results in about 6 months, with sales expected starting in 2026. This looks like a good growth stock to me, trading at a cheap valuation, given the profit from the new products, and I am wondering what your take is on the acquisition and the stock.
Read Answer Asked by Dan on July 30, 2024
Q: Results yesterday from CPH and DR both looked excellent and the stock prices have moved up significantly in response. They both look cheap, particularly CPH, even more so if you ex out the $2.20 cash on the balance sheet. What do you think of these as part of a small cap portfolio?
Read Answer Asked by Dan on March 19, 2024
Q: Doing a year end review of all of my holdings. I would like to reduce my position in several stocks (or eliminate entirely in the case of HR.UN and CPH) in order to raise some cash for increasing my position in several other holdings. Fairly large question, so I will divide it into 2, this for the potential reductions and a further question about the potential adds. Would you please rank these stocks in the order you would reduce or eliminate to raise some cash, starting with the one you would be most inclined to reduce/eliminate. Sector, or large cap/small cap not a concern, as I have a broadly diversified portfolio with a lot (too many, really) of names. Thank you for this, and also for the very good service. My 1st year as a client, and I will certainly be renewing. I have recommended the site to a few friends who also do investing.
Read Answer Asked by Dan on December 20, 2020
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!